CombiMatrix Corporation has received a contract from the Defense Advanced Research Projects Agency to initiate a new program utilizing its array technology and ElectraSense reader. This program is focused on the development of a new application of CombiMatrix's microarray technology and involves the synthesis of molecules known as "aptamers," which are molecules with unique biological properties. Synthesis of aptamers followed by iterative evolution of these molecules, coupled with CombiMatrix's electrochemical-detection techniques, could enable powerful, label-free detection systems that could revolutionize analysis applications such as diagnostics, chemical measurement, as well as biological and chemical agent detection.

CombiMatrix's technologies are said to be well suited for this type of work and the corresponding applications because of the ease with which customized molecules can be synthesized, and re-synthesized with necessary modifications, and the use of electrochemical measurement techniques pioneered by the company.

Other array technologies do not have the functional capabilities of CombiMatrix's technology platform. The amount of the grant for this proof-of-concept study is $250,000.

"This funding will allow us to explore largely uncharted capabilities and applications that are inherent in our core technologies," stated Dr. David Danley, director, Homeland Security and Defense Programs at CombiMatrix. "This seed funding will support a proof-of-concept demonstration of our capabilities. If successful, we will be seeking larger amounts of funding for continued development for this brand-new application of our technology."

CombiMatrix Corporation is a diversified biotechnology business, that develops proprietary technologies, products and services in the areas of molecular diagnostics, nanotechnology research as well as the defense and homeland security markets.

RSS    Save to Del.icio.us  Digg This